The objective of the study is to evaluate the effect of physical exercise on exercise capacity, quality of life and serum NT-proBNP levels in adult patients with congenital heart disease.
ID
Source
Brief title
Condition
- Cardiac disorders, signs and symptoms NEC
- Cardiac and vascular disorders congenital
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome is the change in V*O2peak between patients in the sports
participation group, and the control group.
Secondary outcome
Secondary outcome measures are change in NYHA functional class, quality of
life, and NT-proBNP levels.
The primary safety outcome is the composite of all hospitalizations, and all
deaths during, or within three hours after exercise. The secondary safety
outcome is the composite of all exercise related injuries for which medical
attention is sought.
Background summary
Survival of patients with congenital heart disease has steadily increased over
the past decades, with even those with severe congenital cardiac anomalies
currently reaching adulthood. Many patients have residual lesions of their
cardiac condition, which, in addition to previous cardiac surgery and cyanosis
during childhood, increases their risk to develop heart failure. In patients
with acquired heart failure regular physical
activity decreases both (cardiac) morbidity and mortality. Although the
rationale behind the beneficial effects of physical activity seems equally
applicable to grown-up congenital heart disease (GUCH) patients, no conclusive
evidence exists.
Our previous, small-scaled pilot-study on exercise training in adult patients
with a systemic right ventricle demonstrated an increase in exercise capacity
after a 10-week training program. In addition, exercise training was found to
be safe, even in these complex cardiac patients. Indeed, it seems highly likely
that exercise training will lead to substantial improvements in
(cardiovascular) morbidity in a much broader spectrum of
GUCH patients.
Exercise training studies in acquired heart disease showed that compliance is a
pitfall. To overcome this pitfall, we hypothesized that a training program
should be patient-based. More importantly, by mutual contact through social
media we assume patients to remain involved and motivated. Therefore, we
propose the *ExTra GUCH trial*, as a large-scale, randomized controlled trial,
to evaluate the effect of sports participation on exercise capacity, morbidity
and quality of life in symptomatic GUCH patients. We expect our study to
provide evidence of the benefits of exercise training in GUCH patients, so to
provide these young patients with the best possible cardiovascular care. In
addition, the study will give insight into the
expanding role of social media in cardiovascular care.
Study objective
The objective of the study is to evaluate the effect of physical exercise on
exercise capacity, quality of life and serum NT-proBNP levels in adult patients
with congenital heart disease.
Study design
Multi-centre, prospective, randomised trial with blinded evaluation of patient
outcomes. Follow-up 26 weeks.
Intervention
The ExTra GUCH training protocol is designed to decrease participation
threshold, and increase patient*s ownership. Consenting patients agree with
sports participation three times per week, for 26 consecutive weeks (e.g. six
months). The training schedule is set-up as follows:
Training sessions are individualized, based on the mean heart rate reserve (HRR
= resting heart rate + 0.6[peak heart rate - resting heart rate]) of the HRR at
latest cardiopulmonary exercise test. This ensures optimal individualized
training schedules, and takes into account any possible use of medication. Each
training session takes a minimum of thirty minutes. Patients are requested to
keep a log for the training program, stating dates and times of performed
exercise, and heart rates during exercise.
Previous exercise training studies in acquired heart disease showed that
compliance is a pitfall. To overcome this pitfall two major differences are
incorporated into our study. Firstly, consenting patients can choose their
sport to perform the exercise-training program as they like, as long as the
above mentioned time-criteria are met.
Social media
Secondly, to increase compliance and create solidarity, consenting patients are
added to the enclosed ExTra GUCH Facebook group. The ExTra GUCH Facebook group
is designed to post sportive accomplishments, and study progress. Consenting
patients can post questions, which can be answered by fellow participants, or
the principal investigator. No clinical and/or private information is posted on
the ExTra GUCH Facebook group. The principal investigator manages the ExTra
GUCH Facebook group. Participation in the ExTra GUCH Facebook group is
voluntary, and refusal to participate does not exclude consenting patients from
participation in the trial.
Patients can cease the exercise training at any time and for any reason without
consequences for the patient*s further treatment.
Study burden and risks
Previous studies on exercise in adult patients with congenital heart disease
showed exercise to be safe in this patient population. Exercise related
injuries are to be expected. Although no (major) cardiovascular events are
expected from the proposed study, all events will be noted.
Meibergdreef 9 Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9 Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
Age >= 18 years
Congenital heart disease
NYHA Class II or III
Exclusion criteria
Inability to give informed consent
Inability to participate in an exercise training program
Exercise-induced arrhythmia and/or ischemia
Cyanosis at rest
Pregnancy
Major cardiovascular event and/or procedure within three months previous to inclusion.
Participation in interventional clinical trial
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL53782.018.15 |